HEALTH TECHNOLOGY

REVIV Releases game-changing COVID-19 management software

REVIV | December 14, 2020

Because of worries over the Government's contact tracing framework and the struggling organizations in the UK, Sarah Lomas, the President and CEO of REVIV, devoted the organization's endeavors to give an answer to the UK as well as across the world. In a joint effort with a bleeding edge advancement group, driven by tech master Idan Udi Edry, REVIV has made HELIIX - the most strong and successful management programming presently available.

 

REVIV, the world-driving organization in precaution wellbeing, is dispatching a COVID-19 management answer for organizations. The pandemic hit and REVIV responded to bring a not-for-benefit helpline worked by their master clinical experts, not-revenue driven PCR and immunizer testing at a straightforward and top notch cost of £89. Also, presently they're pleased to dispatch HELIIX an imaginative COVID-19 danger profiling and management framework to get representatives back in the work place securely.

 

The turn out of the invited immunization started a week ago yet it very well may be a long time before the UK's overall labor force may get it. HELIIX is the ideal arrangement while we are as yet doing combating the Covid.

 

REVIV is most popular in the UK for their IV and promoter shot treatments and far reaching hereditary testing. Presently HELIIX is offering organizations shrewd danger profiling, powerful following and case management, debilitated compensation anticipating, client disconnection cautions thus significantly more inside the product framework - all workers need to do is download and update the app on their telephone for continuous functionality.

 

Non-Executive Board Director Max Johnson says: "All employers need a COVID-19 management software to make their companies run smoothly and safely. We think HELIIX is just the software to enable them to do that."

 

Professional functionality of HELIIX is charged at just £1.40 per user a month. All subscriptions are free to cancel at any time.

 

Sarah was recently on the popular BBC documentary, Manctopia: Billion Pound Property Boom. She shared her story of growing up poor in Manchester and returning years later to establish the HQ of a global health and wellness company worth £100m. Sarah also recently spoke to Business Live about the discrimination she faced over her northern accent during her banking career, which led her to leave the country to work abroad only returning to set up the REVIV HQ.

Spotlight

Most of the more than 2,000 primary care providers surveyed by the Commonwealth Fund and Kaiser Family Foundation say new care delivery models are having a positive impact on the quality of care they deliver to their patients. Yet, many remain unconvinced, suggesting that the proponents of the new care delivery models need to do more to enable those new models to work for both patients and providers.


Other News
MEDICAL DEVICES, HEALTHCARE ANALYTICS

The Garage enters strategic partnership with Morris Heights Health Center in an effort to change healthcare in underserved Bronx, NY

Garage and Morris Heights Health Center (MHHC) | December 05, 2022

Population health management platform company, the Garage, announced that it is joining forces with federally qualified health center, Morris Heights Health Center (MHHC). The Bronx-based MHHC serves over 50,000 patients, and its mission is to be the vanguard for quality, affordable, and accessible health care for all. MHHC will be utilizing the Garage’s proven population health management platform, Bridge, for empowering better care in the community. The SaaS platform connects providers, care teams and enables real-time patient information exchange, facilitates referral management, secure messaging, patient tracking and communication, clinical data management, clinical integration, clinical intelligence, and clinical analytics. “We are excited to partner with the Garage. We needed a solution that would help us better serve our patients and prepare us for the opportunities ahead in value-based care. Their proven credentials along with the depth of their platform made this decision a no-brainer.” Mari Millet, President and CEO of MHHC MHHC’s utilization of Bridge will start with a focus in care management for all of its patients and will be another implementation of the Garage’s Digital-First, Data-First approach, which focuses on the Quintuple Aim – Lower Costs of Care, Better Care for the Patient, Improved Health of Communities, Sustainable Service Model for Care Teams, and Equitable Access to Care for All. “Our mission to change healthcare for good…one community at a time is realized by partnerships like this,” said Pranam Ben, Founder and CEO of the Garage. “MHHC’s commitment to their patients presents a great opportunity for us to architect a data driven, platform-based, collaborative care model for the Bronx community.” About the Garage Based in Orlando, Florida, the Garage is a population health management technology company dedicated to changing healthcare for good…one community at a time. The company works with more than 140+ healthcare organizations and 19,500+ providers across 34 states. Through its collaborative population health management platform, Bridge, the Garage touches more than 15 million patient lives. About Morris Heights Health Center MHHC is a non-profit organization funded by federal, state, and foundation grants as well as private and corporate donors. They serve more than 50,000 patients annually and provide a wide range of primary, specialty, dental, mental health, educational, and social services at thirteen locations throughout the Bronx.

Read More

MEDICAL DEVICES

Study Reveals Florence Healthcare’s Site Enablement Platforms Can Accelerate Clinical Trials by Six Weeks and Reduce Costs by Over $1M per Study

Florence Healthcare | November 18, 2022

Florence Healthcare™, a clinical research technology company headquartered in Atlanta, Georgia, announced the completion of a year-long third-party study on the impact of Site Enablement Platforms™ on clinical research timelines and costs. The study by Marketcap Consulting is the first to compare how traditional site management approaches differ from site-first Site Enablement Platforms. The study looked at the impact of traditional sponsor portals and new Site Enablement Platforms on research sponsor and Contract Research Organization study timelines and budgets. “Pharma sponsors and CROs realize the importance of enabling sites to do their best work - but only recently have they discovered that traditional site portals are more hindrance than help. Yet, these organizations weren't able to measure the true impact of switching to a Site Enablement Platform. This year-long study aimed to fix that and highlight how linking fragmented workflows accelerates the full lifecycle of clinical trials.” Ryan Jones, CEO of Florence Healthcare Site enablement is a new technology category that prioritizes the needs of the site, a major shift from past technology that only looked at the experience of the sponsor. These platforms, including Florence Healthcare’s SiteLink™, insist on ease-of-use and ease-of-setup for the site, quality support, and simplified integrations. SiteLink works in conjunction with eBinders™, an electronic Investigator Site File solution used by over 12,000 research sites in 45 countries. About the Study Marketcap Consulting conducted interviews with clinical research operations leaders harnessing SiteLink, examined timelines and study costs, and analyzed the impact across the sites in the study. On average, the team found that SiteLink accelerated study start-up by four weeks and study close-out by two weeks at every site. For a 50-site study, this six-week acceleration reduced cash burn by one million dollars. “We can see a clear positive impact on study timelines and cash burn when research sponsors and CROs implement Site Enablement Platforms,” said Joel White, founder of Marketcap Consulting. “This early study reveals that by enabling sites to do their best work, the clinical research industry unlocks value across the full research cycle.” “While the financial impact of switching to SiteLink makes investing in site enablement an easy choice for sponsors and CROs, it’s really the acceleration of studies that gets our team at Florence Healthcare excited,” said Jones. “We aim to double the output of research teams by the end of the decade, and enabling sites is the way to do it.” About Florence Healthcare Florence Healthcare’s clinical trial software helps more than 12,000 research sites in 45 countries manage their documents, data, and workflows. The Florence Healthcare™ platform also provides remote access so sponsors and Contract Research Organizations can collaborate with their sites around the world. Florence Healthcare users now perform 5.8 million remote monitoring activities each month.

Read More

HEALTH TECHNOLOGY

Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA

Antengene Corporation Limited | September 19, 2022

Antengene Corporation Limited a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, announced that ATG-101, the company's in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. This ODD will help Antengene facilitate regulatory communication with the FDA, accelerate the clinical development and the future registration of ATG-101. At present, no PD-L1/4-1BB bispecific antibody has been approved for the treatment of pancreatic cancer worldwide. Orphan Drugs, also known as Rare Disease Drugs, refers to pharmaceutical products developed for the prevention, diagnosis, and treatment of rare diseases or conditions. Orphan Drug Designations by the U.S. FDA are meant to support the development of drug candidates that could potentially bring substantial therapeutic benefits to patients with rare diseases and to provide incentives to the subsequent development, registration and commercialization to designated drugs. Those incentives include tax credit on expenditures incurred in clinical studies, a waiver of the New Drug Application (NDA) fee, and 7-year market exclusivity in the U.S. regardless of the patent status of the designated drug. Pancreatic cancer is a highly malignant type of gastrointestinal cancer. According to the statistics by the World Health Organization (WHO), pancreatic cancer was ranked 13th and 7th globally by its incidence and mortality rates in 2012. In 2018, the U.S. reported over 55,000 newly- diagnosed pancreatic cancer cases and 44,330 related deaths. Whereas still defined as an orphan disease currently, it is projected that by 2030, pancreatic cancer will become the second most common cause of cancer-related deaths. ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile. In preclinical studies, ATG-101 demonstrated significant anti-tumor activity in animal models of resistant tumors as well as those that had progressed on anti-PD-1/L1 treatment. Furthermore, ATG-101 has also shown an excellent safety profile in Good Laboratory Practice (GLP) toxicology studies. ATG-101 is the first PD-L1/4-1BB bispecific antibody entering clinical development in Australia and is currently being evaluated in clinical studies in Australia, China, and the U.S. "We are very encouraged by this Orphan Drug Designation from the U.S. FDA and are hopeful that ATG-101 will offer a novel therapeutic to patients with pancreatic cancer. As Antengene's first in-house developed asset with global rights, ATG-101 has already entered clinical development in Australia, China, and the U.S. We will strive to accelerate the global clinical development of ATG-101 in efforts to provide a new treatment option to patients around the world." Dr. Bo Shan, Antengene's Chief Scientific Officer About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a broad and expanding pipeline of 15 clinical and preclinical assets, of which 10 are global rights assets, and 5 came with rights for Asia Pacific markets including the Greater China region. To date, Antengene has obtained 24 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® already approved in mainland China, South Korea, Singapore and Australia.

Read More

HEALTHTECH SECURITY

Zócalo Health’s Culturally Competent Virtual Healthcare Services for Latino Communities Now Available

Zócalo Health | October 12, 2022

Zócalo Health, a Latino-founded healthcare service designed for Latino patients, announced the launch of its primary care memberships for residents across California and Texas. Starting members can access same day virtual care visits and care navigation services via Zócalo’s website, introducing the Latino community to an improved and long overdue healthcare experience built on trust, relationships, and culture. Zócalo Health, which premiered as an invite-only service to select members earlier this summer, was founded by Erik Cardenas and Mariza Hardin to strengthen the health and wellbeing of the Latino community by eliminating barriers to high-quality healthcare services. This multi-state launch demonstrates the company’s continued commitment to delivering affordable and accessible primary care that blends tradition with innovation and prioritizes trusting relationships between providers and patients. Members will have access to a range of services and care options that would typically be addressed in primary care including: mental health conditions, preventative and lifestyle needs, chronic disease management, urgent care, and other more specific health conditions. The Zócalo primary care model includes the use of community health workers (CHWs) – or as they’re known in the Latino community, promotores de salud. Research shows CHWs are crucial to helping health systems achieve their full potential, since they work to connect patients to local resources and care. At Zócalo, promotores work individually with members to coordinate their care across a team of physicians, nurses, and mental health therapists, as well as connect members to needed resources across the community. Clinicians and promotores are hired from the communities they serve and can provide culturally competent care in both English and Spanish. By building care teams that come from and look like the communities they serve, the team is better able to foster a primary care relationship with patients. Once care has been established with Zócalo Health, members have 24/7 access to chat with their promotor de salud to receive individual guidance on personal health goals and needs. “Today, I am immensely proud to open up Zócalo Health’s services to the community. As a kid, I remember the long waits in the community health clinic to see a doctor who often did not speak Spanish. I had to act as a translator for my mom about my own care and help her navigate next steps. I felt guilty that my mom had to take time off from work for my appointment and pay for any prescriptions or additional care needed. For my family, no work meant no pay, so a doctor’s visit was a heavy burden on everyone,” said Zócalo Health CEO Erik Cardenas. “As the landscape for healthcare delivery has changed with technology, our community continues to get left behind. The one-size-fits-all model for healthcare doesn’t work for everyone. I owe it to my parents and my family to do better. Zócalo Health is focused on giving our people a community built around their healthcare needs.” Despite the major cultural impact the Latino population has had on the U.S., and their increased spending power year after year, the U.S. healthcare system has been slow to adapt its services to the needs of this community’s unique health and cultural needs. Latinos still experience disproportionate barriers to healthcare access, particularly in primary care, where the average wait time to see a doctor is 24 days. This long delay, combined with fewer in-person appointments, high-deductible plans, and high out-of-pocket fees, results in many Latino patients avoiding treatment, using informal networks (family/friends), or waiting for hours in expensive emergency rooms to seek care. In addition to the existing disparities in healthcare access, the COVID-19 pandemic and resulting economic impact have exacerbated health inequities for the Latino community, particularly when it comes to accessing high-quality primary care and preventative services. “I’ve always been community-oriented and my role as a promotora gives me the opportunity to help other Latinos manage their health and navigate a system that unfortunately has not adapted to our needs. “I’m so excited to be able to guide my community through what can often be a stressful experience in order to deliver personalized care management from someone who understands our culture and needs. Our Zócalo Health team is ready to advocate for our members and ultimately impact our community’s health, one person at a time.” Zócalo Health promotora Caroline Carbajal Zócalo Health’s membership and payment options are designed to make access to primary care easy and affordable for Latinos. Services are offered through monthly memberships, with pricing starting at $40 per month or at a discounted rate of $420 a year when paid upfront. Patients in California and Texas can now purchase a membership and schedule same-day virtual appointments by visiting zocalo.health. Zócalo Health plans to expand to other states in 2022 and beyond. About Zócalo Health Zócalo Health is a Latino-founded healthcare service designed for the Latino patient. Our primary care model blends tradition with innovation and prioritizes trusting relationships between care teams and patients. Each member of Zócalo Health is paired with a promotor de salud (community health worker) to establish a relationship to better understand members’ goals and connect them to a Zócalo Health physician. Our team of physicians, hired from the community, focus on prevention, primary care, behavioral health, and traditional practices that work together to support our members’ wellness. Operating in the states of California and Texas, Zócalo Health offers affordable and convenient care memberships that provide same-day access to culturally-aligned providers.

Read More

Spotlight

Most of the more than 2,000 primary care providers surveyed by the Commonwealth Fund and Kaiser Family Foundation say new care delivery models are having a positive impact on the quality of care they deliver to their patients. Yet, many remain unconvinced, suggesting that the proponents of the new care delivery models need to do more to enable those new models to work for both patients and providers.

Resources